<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00172107</url>
  </required_header>
  <id_info>
    <org_study_id>CL1-11-821</org_study_id>
    <nct_id>NCT00172107</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis</brief_title>
  <official_title>A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of&#xD;
      3 doses of ALX1-11 (recombinant human parathyroid hormone [rhPTH(1-84)])(50, 75 and 100 µg)&#xD;
      in the treatment of postmenopausal osteoporosis. The primary objective of this study is to&#xD;
      compare the efficacy of ALX1-11 (50, 75 and 100 µg) with that of placebo in terms of&#xD;
      increasing vertebral bone mineral density, when given daily by subcutaneous injection for 12&#xD;
      months in postmenopausal women with osteoporosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human clinical experience with a synthetic human parathyroid hormone fragment (rhPTH 1-34)&#xD;
      and animal studies with ALX1-11 demonstrate consistent increases in bone mineral density.&#xD;
      Furthermore, the newly formed bone is normal in structure and composition. Therefore, ALX1-11&#xD;
      (recombinant human parathyroid hormone [rhPTH 1-84]) has the potential to stimulate new bone&#xD;
      formation in osteoporotic patients thereby increasing trabecular bone density and preventing&#xD;
      fractures. The clinical profile for ALX1-11 can be expected to be unique, since none of the&#xD;
      approved therapies for osteoporosis are able to form the quantities of new bone that ALX1-11&#xD;
      is potentially capable of. Patients with bone density below the &quot;fracture threshold&quot;&#xD;
      (osteopenia), as well as those with established vertebral fractures (osteoporosis), would be&#xD;
      expected to benefit from treatment.&#xD;
&#xD;
      Animal toxicology studies have been completed and there were no results to indicate any&#xD;
      restrictions in the clinical usage of the drug. Preliminary human clinical experience with&#xD;
      ALX1-11 in healthy, postmenopausal females has demonstrated no apparent risk of frank&#xD;
      hypercalcemia* at single administrations up to 5.0 µg/kg or daily administrations for 7 days&#xD;
      up to 2.0 µg/kg/day.&#xD;
&#xD;
      Based on these studies, the anticipated therapeutic range of ALX1-11 is 50-100 µg per day&#xD;
      (approx. 1.0 - 1.5 µg/kg/day). Therefore, the dose range to be tested in this study will&#xD;
      include an anticipated minimally effective dose, interim dose and maximally tolerable dose&#xD;
      (50, 75 and 100 µg). The efficacy of 3 doses of ALX1-11 will be assessed in terms of bone&#xD;
      mineral density and biochemical markers of bone turnover in postmenopausal women.&#xD;
&#xD;
      The primary objective of this study is to determine the dose-response relationship of ALX1-11&#xD;
      in terms of bone mineral density. The efficacy of the 3 doses of ALX1-11 relative to placebo&#xD;
      will be determined by measurement of bone mineral density (by DXA) at baseline and at 3, 6&#xD;
      and 12 months.&#xD;
&#xD;
      Patients will administer a daily subcutaneous injection of 0.5 mL of either 50, 75 or 100 µg&#xD;
      of ALX1-11 or placebo every morning for 12 months.&#xD;
&#xD;
      Women will be advised to use the provided calcium supplements (500mg elemental calcium) to&#xD;
      maintain a total daily intake of 1000-1500 mg/day and vitamin D supplements will also be&#xD;
      provided (400 IU/day). A dietary questionnaire will be done at visit screen, 6 and 15.&#xD;
&#xD;
      If a patient's total serum calcium measurement, during the treatment phase, demonstrates&#xD;
      frank hypercalcemia OR if her pre-dose calcium levels are more than 0.5 mg/dL or 0.125 mmol/L&#xD;
      above the upper limit of normal (2.78 mmol/L or 11.1 mg/dL), then the patient's serum calcium&#xD;
      level must be repeated.&#xD;
&#xD;
      If upon re-test a patient continues to demonstrate frank hypercalcemia OR if her basal&#xD;
      pre-dose calcium levels continues to be elevated above the upper limit of normal, then the&#xD;
      patient will be withdrawn from the study.&#xD;
&#xD;
      *Frank Hypercalcemia: defined as total serum calcium levels above 11.1 mg/dL or 2.78 mmol/L&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 1995</start_date>
  <completion_date type="Actual">March 24, 1997</completion_date>
  <primary_completion_date type="Actual">March 24, 1997</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy was assessed as percent change from baseline in BMD, BMC, and BMA at the lumbar spine, total hip, femoral neck and whole body (excluding the head) using DXA.</measure>
    <time_frame>12 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy evaluations were also performed at Month 3, 6, and 12: Percent change from baseline in lumbar spine BMC and BMA; Percent change from baseline in total hip and femoral neck BMD, BMC and BMA</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drug injectable subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mcg PTH(1-84)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mcg PTH(1-84)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mcg PTH(1-84)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALX1-11 50 mcg</intervention_name>
    <description>PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen</description>
    <arm_group_label>2</arm_group_label>
    <other_name>PREOS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo powder for subcutaneous injection</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALX1-11 75mcg</intervention_name>
    <description>PTH(1-84)75 mcg for subcutaneous injection</description>
    <arm_group_label>3</arm_group_label>
    <other_name>PREOS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALX1-11</intervention_name>
    <description>PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen</description>
    <arm_group_label>4</arm_group_label>
    <other_name>PREOS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post-menopausal women aged 50-75 years at Visit 1 (at least 5 years post cessation of&#xD;
             menses, or FSH&gt;20 IU/L, serum estradiol &lt;110 pmol/L)&#xD;
&#xD;
          -  Vertebral bone mineral density at least 2.5 S.D. below the mean of young normals.&#xD;
             Patients must have at least 2 measurable contiguous vertebral bodies in the lumbar&#xD;
             region, L1-L4.&#xD;
&#xD;
          -  Ability to self administer injections&#xD;
&#xD;
          -  Ability and willingness to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of 5 or more vertebral fractures&#xD;
&#xD;
          -  Evidence of 2 or more vertebral fractures in the region L1-L4&#xD;
&#xD;
          -  Presence of significant cardiac disease as determined by history, physical examination&#xD;
             and laboratory screens e.g. cardiac dysrhythmias.&#xD;
&#xD;
          -  Presence of significant hepatic, renal, pulmonary, gastrointestinal, hematological,&#xD;
             endocrine, immunologic, neurological or psychiatric disease as determined by history,&#xD;
             physical examination and laboratory screens. Specifically excluded are diseases known&#xD;
             to contribute to osteoporosis: hyperparathyroidism, hyperthyroidism, glucocorticoid&#xD;
             excess, hyper or hypocalcemia, Paget's disease, osteogenesis imperfecta, osteomalacia&#xD;
             and severe scoliosis.&#xD;
&#xD;
          -  Evidence of lumbar fusions, osteophytes or excessive degenerative disease which&#xD;
             precludes reasonable DXA measurement.&#xD;
&#xD;
          -  History or presence of cancer within the previous 5 years except for superficial basal&#xD;
             cell and squamous cell carcinomas of the skin.&#xD;
&#xD;
          -  Treatment with any of the following therapies:&#xD;
&#xD;
               -  Any form of Estrogen within previous 6 months&#xD;
&#xD;
               -  Prior use of Etidronate for more that 2 treatment cycles (2weeks/cycle) and/or&#xD;
                  any use within prior 6 months&#xD;
&#xD;
               -  Any other bisphosphonate&#xD;
&#xD;
               -  Parathyroid Hormone use within 6 months&#xD;
&#xD;
               -  Fluoride (&gt;10 mg/day) within 12 months&#xD;
&#xD;
               -  Any form of Calcitonin within previous 4 months&#xD;
&#xD;
               -  Thyroid hormone within previous 4 months unless TSH levels found to remain within&#xD;
                  normal range&#xD;
&#xD;
               -  Other therapies known to influence bone metabolism* within previous 4 months&#xD;
&#xD;
               -  Any investigational compound within previous 3 months&#xD;
&#xD;
               -  Abnormal serum Ca++ level: patients having two (2) consecutive serum calcium&#xD;
                  above 2.66 mmol/L (10.6 mg/dl) will be excluded.&#xD;
&#xD;
               -  History of positive test for Hepatitis B or C, or urine drug screen.&#xD;
&#xD;
               -  History of alcohol or drug abuse: an excess of alcohol is defined as more than 4&#xD;
                  or any combination of more than four (4) of the following per day: 120 mL wine,&#xD;
                  360 mL beer or wine cooler or 30 mL whiskey.&#xD;
&#xD;
               -  Weight more than 25% above ideal body weight, (minimum 45 kg) as listed in the&#xD;
                  Metropolitan Life Insurance Tables (Appendix 3)&#xD;
&#xD;
               -  Deemed unsuitable, in the opinion of the investigator, for any other reason.&#xD;
&#xD;
        (*Chronic or continued use of medication that may affect bone calcium metabolism, e.g.&#xD;
        thiazide diuretics, oral or injectable steroids, antimitotics (methotrexate), heparin,&#xD;
        anticonvulsants and supplements of Vitamin D in excess of 1,000 IU per day and Vitamin A in&#xD;
        excess of 10,000 IU per day)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pivotal Research</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda Osteoporosis Research Clinic</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven Harris</name>
      <address>
        <city>Mill Valley</city>
        <state>California</state>
        <zip>94941</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul Miller</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longmont Medical Research Network</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Stuart</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34996</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Center for Osteoporosis Research and Education of St. Joseph's Hospital</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>'Bethesda Health Research Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen Hayes Hospital</name>
      <address>
        <city>West Haverstraw</city>
        <state>New York</state>
        <zip>10993</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Osteoporosis Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simona Scumpia</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>'Diabetes &amp; Glandular Disease Research Associates, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Lipid Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heritage Medical Research Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osteoporosis Research Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-menopausal</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Parathyroid Hormone</keyword>
  <keyword>PTH</keyword>
  <keyword>ALX1-11</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parathyroid Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

